Regular ArticleThe HMG-CoA Reductase Inhibitor Pravastatin Stimulates Insulin Secretion through Organic Anion Transporter Polypeptides
References (31)
- et al.
Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture
Biochem. Pharmacol.
(1992) - et al.
Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2
J. Biol. Chem.
(1998) - et al.
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1
J. Biol. Chem.
(1999) - et al.
Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2)
FEBS Lett.
(1999) - et al.
CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2 + ]i, and insulin secretion
J. Biol. Chem.
(1999) - et al.
Cholesterol content regulates acrosomal exocytosis by enhancing Rab3A plasma membrane association
Dev. Biol.
(2005) - et al.
CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
Biochim. Biophys. Acta
(1986) - et al.
The effect of 6 months of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study
Clin. Ther.
(2006) - et al.
Pioglitazone improves insulin secretory capacity and prevents the loss of betacell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress
Metabolism
(2004) - et al.
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liverspecific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters
J. Biol. Chem.
(1999)
Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types
Biochim. Biophys. Acta
Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome
Biomed. Pharmacother.
Effect of pravastatin on the development of diabetes and adiponectin production
Atherosclerosis
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
N. Engl. J. Med.
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
Circulation
Cited by (20)
Bioconversion of mevastatin to pravastatin by various microorganisms and its applications – A review
2018, Biocatalysis and Agricultural BiotechnologyCitation Excerpt :Clinically, pravastatin administration also increased adiponectin levels and reduced urinary protein excretion (Sakamoto et al., 2006). The serum glucose level during oral glucose tolerance test (OGTT) was significantly decreased by pravastatin treatment the improvement of OGTT results by pravastatin is attributed to the protective effect on insulin secretion of high-fat/glucose-loaded β-cells, in addition to improving insulin tolerance (Abe et al., 2010). It is less myotoxic than lovastatin and simvastatin, which may be related to its relatively poor uptake by muscle cells (Masters et al., 1995).
Modulation of adiponectin as a potential therapeutic strategy
2014, AtherosclerosisCitation Excerpt :For example, pravastatin increased circulating adiponectin levels in humans, whereas simvastatin did not [5]. Another study showed that pravastatin enhanced the glucose-stimulated insulin secretion from INS-1 cells and improved glucose intolerance and insulin resistance in fat-loaded db/db mice [60]. In contrast, some statins (particularly at high doses) caused unfavorable pleiotropic effects, including reduced insulin secretion and exacerbation of insulin resistance [61].
Murine models for pharmacological studies of the metabolic syndrome
2013, Pharmacology and TherapeuticsDifferential effects of OATP2B1 on statin accumulation and toxicity in a beta cell model
2024, Toxicology Mechanisms and MethodsTherapy for CKD and DKD
2023, Folia Pharmacologica Japonica